Is hyperbaric oxygen or ozone effective in experimental endocarditis?

Ozkan M. T. A., Vural A., Cicek O. F., Yener A. U., ÖZCAN S., Toman H., ...Daha Fazla

JOURNAL OF SURGICAL RESEARCH, cilt.202, sa.1, ss.66-70, 2016 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 202 Sayı: 1
  • Basım Tarihi: 2016
  • Doi Numarası: 10.1016/j.jss.2015.12.006
  • Dergi Adı: JOURNAL OF SURGICAL RESEARCH
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.66-70
  • Çanakkale Onsekiz Mart Üniversitesi Adresli: Evet

Özet

Background: Infective endocarditis, a disease with high mortality and morbidity, is most commonly caused by Staphylococcus aureus; mortality and morbidity further increase in the presence of methicillin-resistant strains of S. aureus. Linezolid is the first of the oxazolidinones, a new antibiotic group that has been approved for the treatment of infections caused by gram-positive cocci. Linezolid reduces the quantity of microorganisms in vegetation to some extent; in addition, the use of hyperbaric oxygen (HBO) and ozone (O-3) therapies is likely to improve targeted antibacterial effect.